Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Linezolid.

G French1

  • 1Department of Infection, St Thomas' Hospital, London, UK.

International Journal of Clinical Practice
|February 24, 2001
PubMed
Summary
This summary is machine-generated.

Linezolid, a novel oxazolidinone antibiotic, shows efficacy against multidrug-resistant Gram-positive bacteria, including hospital-acquired infections. Its favorable pharmacokinetics and safety profile make it a promising option for treating resistant infections.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Making a difference in the real world. User-centred impact evaluation of an eight-country, community-based early childhood programme.

Evaluation and program planning·2022
Same author

Antibiotic Guidelines.

Journal of the Royal College of Physicians of London·2019
Same author

A European survey of antibiotic management of methicillin-resistant Staphylococcus aureus infection: current clinical opinion and practice.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2010
Same author

Guidelines for the management of hospital-acquired pneumonia in the UK: report of the working party on hospital-acquired pneumonia of the British Society for Antimicrobial Chemotherapy.

The Journal of antimicrobial chemotherapy·2008
Same author

Multifocal benign notochordal cell tumours.

Histopathology·2007
Same author

Difficulty in brainstem death testing in the presence of high spinal cord injury.

British journal of anaesthesia·2004
Same journal

RETRACTION: Prediction of Arrhythmia Recurrence after Atrial Fibrillation Ablation in Patients with Normal Anatomy of the Left Atrium.

International journal of clinical practice·2025
Same journal

Clinical Outcomes Based on the Attainment of Low-Density Lipoprotein Cholesterol Targets in Patients with Acute Coronary Syndrome in Real-World Practice.

International journal of clinical practice·2025
Same journal

Knowledge and Awareness of Osteoporosis: A Survey of Physical Therapy Providers in Saudi Arabia.

International journal of clinical practice·2024
Same journal

Efficacy and Safety of Pericapsular Nerve Group Block for Hip Fracture Surgery under Spinal Anesthesia: A Meta-Analysis.

International journal of clinical practice·2024
Same journal

The Role of Pharmaceutical Innovation in Clinical Practice Guidelines for Chronic Diseases.

International journal of clinical practice·2024
Same journal

Blood Features Associated with Viral Infection Severity: An Experience from COVID-19-Pandemic Patients Hospitalized in the Center of Iran, Yazd.

International journal of clinical practice·2024
See all related articles

Area of Science:

  • Microbiology
  • Infectious Diseases
  • Pharmacology

Background:

  • Rising global antibiotic resistance in Gram-positive bacteria, particularly in hospital settings.
  • Emergence of vancomycin-resistant enterococci and vancomycin-intermediate Staphylococcus aureus necessitates new therapeutic options.
  • Glycopeptides like vancomycin are often last-resort treatments for resistant Gram-positive infections.

Purpose of the Study:

  • To introduce linezolid, a novel oxazolidinone antibiotic, as a potential treatment for multidrug-resistant Gram-positive bacteria.
  • To highlight linezolid's activity against clinically significant resistant Gram-positive pathogens.
  • To review linezolid's pharmacokinetic properties, safety profile, and clinical trial outcomes.

Main Methods:

  • Review of linezolid's chemical properties and mechanism of action.

Related Experiment Videos

  • Analysis of in vitro activity against resistant Gram-positive strains.
  • Evaluation of pharmacokinetic data, including bioavailability and dosing considerations.
  • Summary of clinical trial results for various infection types.

    • Main Results:

    • Linezolid demonstrates broad-spectrum activity against all clinically important Gram-positive bacteria, including resistant strains.
    • The drug exhibits favorable pharmacokinetics with equal oral and intravenous bioavailability and no renal dose adjustment needed.
    • Clinical trials show excellent efficacy in treating skin and soft tissue, respiratory, and bloodstream infections.
    • Linezolid possesses a good safety profile.

    Conclusions:

    • Linezolid represents a significant advancement in the treatment of multidrug-resistant Gram-positive bacterial infections.
    • Its efficacy, safety, and pharmacokinetic advantages position it as a valuable therapeutic agent.
    • Combined with infection control and judicious antibiotic stewardship, linezolid can aid in combating resistant Gram-positive bacteria.